These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7240807)

  • 1. Influenza B virus vaccines in children and adults: adverse reactions, immune response, and observations in the field.
    Foy HM; Cooney MK; Allan ID; Frost F; Blumhagen JM; Fox JP
    J Infect Dis; 1981 May; 143(5):700-6. PubMed ID: 7240807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response to influenza A/New Jersey and A/Victoria virus vaccines in 1976 and subsequent antibody levels after influenza A epidemics, 1977-1979.
    Foy HM; Cooney MK; Taylor J; Allan I; Chuang TY; Blumhagen J; Fox JP
    J Infect Dis; 1980 Aug; 142(2):139-44. PubMed ID: 7410896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.
    Sugaya N; Nerome K; Ishida M; Matsumoto M; Mitamura K; Nirasawa M
    JAMA; 1994 Oct; 272(14):1122-6. PubMed ID: 7933325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
    N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children.
    Gross PA; Ennis FA; Gaerlan PF; Denson LJ; Denning CR; Schiffman D
    J Infect Dis; 1977 Nov; 136(5):623-32. PubMed ID: 335000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus.
    Feldman S; Wright PF; Webster RG; Roberson PK; Mahoney J; Thompson J; Doolittle M; Lott L; Johnson P; Christoph RC
    J Infect Dis; 1985 Dec; 152(6):1212-8. PubMed ID: 3905983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study.
    Sundaram ME; Meydani SN; Vandermause M; Shay DK; Coleman LA
    Nutr Res; 2014 Feb; 34(2):149-54. PubMed ID: 24461316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A/USSR and B/Hong Kong vaccine. Field experiences during an A/Brazil and an influenza B epidemic.
    Foy HM; Allan I; Blumhagen JM; Cooney MK; Hall C; Fox JP
    JAMA; 1981 May; 245(17):1736-40. PubMed ID: 6163876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence.
    Cate TR; Couch RB; Kasel JA; Six HR
    J Infect Dis; 1977 Dec; 136 Suppl():S450-5. PubMed ID: 342620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season.
    DiazGranados CA; Dunning AJ; Jordanov E; Landolfi V; Denis M; Talbot HK
    Vaccine; 2013 Jan; 31(6):861-6. PubMed ID: 23261045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel influenza A (H1N1) vaccine in various age groups.
    Zhu FC; Wang H; Fang HH; Yang JG; Lin XJ; Liang XF; Zhang XF; Pan HX; Meng FY; Hu YM; Liu WD; Li CG; Li W; Zhang X; Hu JM; Peng WB; Yang BP; Xi P; Wang HQ; Zheng JS
    N Engl J Med; 2009 Dec; 361(25):2414-23. PubMed ID: 19846844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
    Aichinger G; Grohmann-Izay B; van der Velden MV; Fritsch S; Koska M; Portsmouth D; Hart MK; El-Amin W; Kistner O; Barrett PN
    Clin Vaccine Immunol; 2015 Jan; 22(1):46-55. PubMed ID: 25355797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
    Monto AS; Petrie JG; Cross RT; Johnson E; Liu M; Zhong W; Levine M; Katz JM; Ohmit SE
    J Infect Dis; 2015 Oct; 212(8):1191-9. PubMed ID: 25858957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
    Beutner KR; Rizzone C; DeMello S; Ogra PL
    Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.